Chronic kidney disease: Focus on Africa

Kidney Diseases in the Developing World and Ethnic Minorities

Volumn , Issue , 2005, Pages 137-160

  Naicker, Saraladevi ^a   Bello, Aminu K ^b   El Nahas, Meguid ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84991493015     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (101)

1. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002; 13:37-40.
2. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in United States to the year 2010. J Am Soc Nephrol 2001; 12:2753-2758.
3. Anonymous. K/DOQI clinical practice guidelines for chronic kidney disease, evaluation classification and stratification. Kidney disease outcome quality initiative. Am J Kidney Dis 2002; 39(suppl 2):S1-S266.
4. Easterling RE. Racial factors in the evidence and causation of end-stage renal disease. Trans Am Soc Artif Internal Organs 1977; 23:28-33.
5. Mausner JS, Clark JK, Coles BI, Menduke H. An area wide survey of treated end-stage renal disease. Am J Pub Health 1978; 68:166-169.
6. Rostand SG, Kirk KA, Rutsky E, Pate BA. Racial differences in the incidence and treatment of end stage renal disease. N Engl J Med 1982; 306:1276-1279.
7. Trivedi HS, Pang MM. Discrepancy in the epidemiology of nondiabetic chronic renal insufficiency and end stage renal disease in black and white Americans: the Third National Health and Nutrition Examination Survey and United States Renal Data System. Am J Nephrol 2003; 23(6):448-457.
8. Barsoum RS, Rihan ZE, Ibrahim AS, Lebstein A. Long term intermittent haemodialysis in Egypt. Bull World Health Org 1974; 51:647-654.
9. Abdulla K. Chronic renal failure in Northern Iraq. Iraqi Med J 1979; 27:43-46.
10. Abdullah MS. Development of renal services in Kenya. East Afr Med J 1981; 30:9-10.
11. Barsoum RS. Ethical problems in dialysis and transplantation: Africa. Kjellstrand CM, Dosseter JB, eds. Ethical Problems in Dialysis and Transplantation. Dordrecht, The Netherlands: Kluwer Academic Publishers, 1992:169-182.
12. Naicker S. End stage renal disease in sub-Saharan and South Africa. Kidney Int 2003; 63(suppl 83):S119-S122.
13. Barsoum RS. Renal disease in indigenous populations: North Africa. Nephrology 1998; 4:S29-S32.
14. Mabayoje MO, Bamgboye EL, Odutola TA, Mabadeje AF. Chronic renal failure at the Lagos University Teaching Hospital: a 10 year review. Transplant Proc 1992; 24:1851-1852.
15. Seedat YK. Race, environment and blood pressure: the South African experience. J Hypertens 1998; 1:7-12.
16. Steyn K, Gaziano TA, Bradshaw D, Laubscher R, Fourie J. Hypertension in South African adults: results from the Demographic and Health Survey, 1998. J Hypertens 2001; 19:1717-1725.
17. Plange-Rhule J, Phillips R, Acheampong JW, Saggar-Mallik AK, Cappucio FB, Eastwood JB. Hypertension and renal failure in Kumasi, Ghana. J Hum Hypertens 1999; 13(1):37-40.
18. Nseka M, Tshiani KA. Chronic renal failure in tropical Africa. East Afr Med J 1989; 66:109-114.
19. McLigeyo SO, Kayima JK. Evolution of nephrology in East Africa in the last seventy years-studies and practice. East Afr Med J 1993; 70:362-368.
20. Seedat YK, Naicker S, Rawat R, Parsoo I. Racial differences in the causes of end stage renal failure in Natal. South Afr Med J 1984; 65:956-958.
21. Veriawa Y, du Toit E, Lawley CG, Milne FJ, Reinach SG. Hypertension as a cause of end stage renal failure in South Africa. J Hypertens 1990; 4:379-383.
22. Seedat YK. Ethnicity, hypertension, coronary artery disease and renal diseases in South Africa. Ethnicity Health 1996; 1:349-357.
23. Abdurrahman MB, Babaoye FA, Aikhionbare HA. Childhood renal disorders in Nigeria. Pediatr Nephrol 1990; 4(1):88-93.
24. Adhikari M, Bhimma R, Coovadia HM. Focal segmental glomerulosclerosis in children from KwaZulu/Natal, South Africa. Clin Nephrol 2001; 55:16-24.
25. Seedat YK, Nathoo BC, Parag KB, Naiker IP, Ramsaroop R. IgA nephropathy in Blacks and Indians of Natal. Nephron 1988; 50:137-141.
26. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications. Estimates and projections to the year 2010. Diabet Med 1997; 14:S7-S85.
27. Locatelli F, Del Vecchio L. Natural history and factors affecting the progression of chronic renal failure. El Nahas AM, Anderson S, Harris KPG, eds. Mechanism and Management of Progressive Renal Failure. London: Oxford University Press, 2000:20-79.
28. Klag MJ, Whelton PK, Randall BL, et al. End-stage renal disease in African-Americans and White men: 16-year MRFIT findings. J Am Med Assoc 1997; 277:1293-1298.
29. Buck K, Feehally J. Diabetes and renal failure in Indo-Asians in the UK-a paradigm for the study of disease susceptibility. Nephrol Dial Transplant 1997; 12:1555-1557.
30. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 18:844-850.
31. Iseki K. The Okinawa Screening Program. J Am Soc Nephrol 2003; 7(suppl 2):S127-S130.
32. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end stage renal disease. Kidney Int 2003; 63(4):1468-1473.
33. Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 2004; 65:1870-1876.
34. Haroun MK, Jaar BG, Hoffman SC, Comstack GW, Klag MJ, Coresh J. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 2003; 14:2934-2941.
35. Joint United Nations Program on HIV/AIDS/World Health Organisation. UNAIDS/WHO Annual Report: AIDS Epidemic Update, Dec. 2003.
36. WorldHealth Organisation. WHO/United Nation Global Population Hepatitis C Prevalence Report, 2000.
37. Wellems TE, Miller LH. Two worlds of malaria. N Engl J Med 2003; 349:1496-1498.
38. Chitsulo L, Engels D, Montresor A, Savioli L. The global status of schistosomiasis and its control. Acta Trop 2000; 77(1):41-51.
39. Drobniewski FA, Caws M, Gibson A, Young D. Modern laboratory diagnosis of tuberculosis. Lancet Infect Dis 2003; 3:142-147.
40. Swanepoel CR, Naicker S, Moosa R, Katz I, Suleiman SM, Twahir M. Nephrotoxins in Africa. De Broe, Porter, Bennett, Verpooten, eds. Clinical Nephrotoxins. 2nd ed. Dordrecht, Boston, London: Kluwer Academic Publishers, 2003:603-610.
41. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population:third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41:1-12.
42. Coovadia HM, Adhikari M, Morel-Maroger L. Clinico-pathological features of the nephrotic syndrome in South African children. Q J Med 1979; 48:77-91.
43. Bhimma R, Coovadia HM, Adhikari M. Nephrotic syndrome in South African children: changing perspectives over 20 years. Pediatr Nephrol 1997; 11(4):429-434.
44. Meyers AM, Furman KI, Botha JR, Milne FJ, Thomson PD, Louridas G, et al. The treatment of end stage renal disease at the Johannesburg Hospital:a 17 year experience. Part 1. The role of dialysis. South Afr Med J 1983; 64:515-521.
45. Coles GA, El Nahas AM. Clinical interventions in chronic renal failure. El Nahas AM, Anderson S, Harris KPG, eds. Mechanisms and Management of Progressive Renal Failure. London: Oxford Univeristy Press, 2000:401-423.
46. El Nahas AM. Mechanisms of experimental and clinical renal scarring. In:Davison AM, Cameron JS, Grunfeld J-P, et al., eds. Oxford Textbook of Clinical Nephrology. London: Oxford University Press, 1998:1749-1788.
47. Jafar TH, Stark PC, Schmid CH, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001; 60:1131-1140.
48. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, et al. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and non-cardiovascular mortality in general population. Circulation 2002; 106:1777-1782.
49. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. New Engl J Med 1984; 310:356-366.
50. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in essential hypertensives. J Hypertens 1998; 16:1325-1333.
51. Attman P-O. Progression of renal failure and lipids-is there evidence of a link in humans? Nephrol Dial Transplant 1998; 13:545-547.
52. Johnson RJ, Kivlighn SD, Kim YG, Fogo AB. Reappraisal of the pathogenesis and consequence of hyperuricaemia in hypertension, cardiovascular disease and renal disease. Am J Kidney Dis 1999; 33:225-234.
53. Bonnet F, Defrele C, Sassolas A, et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephropathy. Am J Kidney Dis 2001; 37:720-727.
54. Orth SR, Ritz E, Schrier RW. The renal risks of smoking. Kidney Int 1997; 51:1669-1677.
55. Remuzzi G. Cigarrete smoking and renal function impairment. Am J Kidney Dis 1993; 33:807-813.
56. Tofovic SP, Jackson EK. Effects of long-term caffeine consumption on renal function in spontaneously hypertensive heart failure prone rats. J Cardiovasc Pharmacol 1999; 33:360-366.
57. Parekh RS, Klag MJ. Alcohol: role in the development of hypertension and end-stage renal disease. Curr Opin Nephrol Hypertens 2001; 10:385-390.
58. Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ, Atkins RC. Prevalence of kidney damage in Australian adults: the AusDiab Kidney Study. J Am Soc Nephrol 2003; 14:S131-S138.
59. Ramirez SP, Hsu SI, McClellan W. Taking a public health approach to the prevention of end-stage renal disease: the NKF Singapore Program. Kidney Int 2003; 63(suppl 83):S61-S65.
60. Mani MK. Prevention of chronic renal failure at the community level. Kidney Int 2003; 63(suppl 83):S86-S89.
61. Plata R, Silva C, Yahuita J, Perez L, Schieppati A, Remuzzi G. The first clinical and epidemiological programme on renal disease in Bolivia: a model for prevention and early diagnosis of renal diseases in the developing countries. Nephrol Dial Transplant 1998; 13(12):3034-3036.
62. McDonald SP, Maguire GP, Hoy WE. Renal function and cardiovascular risk markers in a remote Australian Aboriginal community. Nephrol Dial Transplant 2003; 18:1555-1561.
63. Stidley CA, Shah VO, Narva AS, et al. A population-based, cross-sectional survey of the Zuni Pueblo: a collaborative approach to an epidemic of kidney disease. Am J Kidney Dis 2002; 39:358-368.
64. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zucchelli P. The angiotensin-converting-enzyme inhibition in Progressive Renal Insufficency Study Group. Effect of the angiotensinconverting- enzyme inhibitor Benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334:939-945.
65. Brown WW, Peters RM, Ohmit SE, Keane WF, et al. Early detection of kidney disease in community settings. The Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2003; 42:22-35.
66. Katz I. Kidney and kidney related chronic diseases in South Africa and chronic disease intervention program experiences. Adv Chronic Kidney Dis 2005; 12(1):14-21.
67. Okoro BA, Okafor HU, Nnoli LU. Childhood nephrotic syndrome in Enugu, Nigeria. West Afr J Med 2000; 19:137-141.
68. Kew MC. Progress towards the comprehensive control of hepatitis B in Africa:a view from South Africa. Gut Suppl 1996; 38(2):S31-S36.
69. Bhimma R, Coovadia HM, Adhikari M. Hepatitis B virus-associated nephropathy in black South African children. Pediatr Nephrol 1998; 11:429-434.
70. Wiggelinkhuizen J, Sinclair-Smith C. Membranous glomerulopathy in childhood. S Afr Med J 1987; 72:184-187.
71. van Buuren AJ, Bates WD, Muller N. Nephrotic syndrome in Namibian children. S Afr Med J 1999; 89(10):1088-1091.
72. Bhimma R, Coovadia HM, Adhikari M, Connolly CA. Impact of HBV vaccine on HBV-associated membranous nephropathy. Arch Pediatr Adolesc Med 2003; 157:1025-1030.
73. Abdel-Wahab MF, Zakaria S, Kamel M, Abdel-Khaliq MK, Mabrouk MA, Salama H, Esmat G, Thomas DL, Strickland GT. High seroprevalence of hepatitis C infection among risk groups in Egypt. Am J Trop Med Hyg 1994; 51(5):563-567.
74. Sabry AA, Sobh MA, Irving WL, Grabowska A, Wagner BE, Fox S, Kudesia G, El Nahas AM. A comprehensive study of the association between hepatitis C virus and glomerulopathy. Nephrol Dial Transplant 2002; 17(2):239-245.
75. Madala ND, Naicker S, Singh B, Naidoo M, Smith AN, Rughubar K. The pathogenesis of membranoproliferative glomerulonephritis in KwaZulu-Natal, South Africa is unrelated to hepatitis C virus infection. Clin Nephrol 2003; 60(2):69-73.
76. Soni PN, Tait DR, Kenoyer DG, Fernandes-Costa F, Naicker S, Gopaul W, Simjee AE. Hepatitis C virus antibodies among risk groups in a South African area endemic for hepatitis B virus. J Med Virol 1993; 40(1):65-68.
77. Cassidy MJ, Jankelson D, Becker M, Dunne T, Walzl G, Moosa MR. The prevalence of antibodies to hepatitis C virus in 2 haemodialysis units in South Africa. S Afr Med J 1995; 85(10):996-998.
78. Moosa MR, Becker M, Cassidy MJD. Hepatitis C virus antibodies in renal allograft recipients. Saudi J Kidney Dis 1996; 7(suppl 1):S141-S144.
79. Ilako FM, McLigeyo SO, Riyat MS, Lile GN, Okoth FA, Kaptich D. The prevalence of hepatitis C virus in renal patients, blood donors and patients with chronic liver disease in Kenya. East Afr Med J 1995; 72(6):362-364.
80. Szczech LA, Kalayjian R, Rodriguez R, Gupta S, Coladonato J, Winston J. Adult AIDS Clinical Trial Group Renal Complications Committee. The clinical complications and antiretroviral dosing patterns of HIV-infected patients receiving dialysis. Kidney Int 2003; 63:2295-2301.
81. Han TM, Naicker S, Ramdial PK, Assounga AGH. Microalbuminuria is a manifestation of HIV-associated nephropathy in South African HIV seropositive patients. Abstracts of the EDTA/ERA Congress, May 2004.
82. Agaba EI, Agaba PA, Sirisena ND, Anteyi EA, Idoko JA. Renal disease in the acquired immunodeficiency syndrome in north central Nigeria. Niger J Med 2003; 12(3):120-125.
83. Appel LJ. Lifestyle modification as a means to prevent and treat high blood pressure. J Am Soc Nephrol 2003; 14:S99-S102.
84. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure:a meta-analysis of randomised, controlled trials. Ann Int Med 2002; 136:493-503.
85. The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, Phase II. Arch Intern Med 1997; 157:657-667.
86. Whelton PK, Appel LJ, Espeland MA, et al. for the TONE Collaborative Research Group. Efficacy of sodium reduction and weight loss in the treatment of hypertension in older persons: main results of the randomised, controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA 1998; 279:839-846.
87. Obarzanek E, Proschan MA, Vollmer WM. Individual blood pressure responses to changes in salt intake: results from the DASH-Sodium trial. Hypertension 2003; 42(4):456-459.
88. Diaz ME. Hypertension and obesity. J Hum Hypertens 2002; 16(suppl 1):S18-S22.
89. Redon J. Hypertension in obesity. Nutr Metab Hypertens 2002; 11:S18-S22.
90. Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414:782-787.
91. King H, Auber RE, Herman WH. Global burden of diabetes, 1995-2025:prevalence, numerical estimates, and projections. Diabetes Care 1998; 21:1414-1431.
92. Motala AA, Pirie FJ, Gouws E, Amod A, Omar MA. Microvascular complications in South African patients with long-duration diabetes mellitus. S Afr Med J 2001; 91(11):987-992.
93. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403.
94. Lindstrom J, Eriksson JG, Valle TT, et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomised clinical trial. J Am Soc Nephrol 2003; 14:S108-S113.
95. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123:754-762.
96. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339:1448-1456.
97. Hsu CY, Lin F, Vittinghof E, Schlipak MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol 2003; 14(11):2902-2907.
98. Zoja C, Corna D, Camozzi D, Cattaneo D, et al. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 2002; 13:2898-2908.
99. Fried LF, Orchard TJ, Kasiske BL, et al. Effects of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59:260-269.
100. Orth SR, Stockmann A, Conradt C, et al. Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int 1998; 54:926-931.
101. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326:1419-1422.